Literature DB >> 7475549

Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection.

H M Diepolder1, R Zachoval, R M Hoffmann, E A Wierenga, T Santantonio, M C Jung, D Eichenlaub, G R Pape.   

Abstract

In acute hepatitis C virus (HCV) infection only 20-50% of patients spontaneously clear the virus. To characterise the immune reaction during that phase we studied the response of peripheral blood mononuclear cells (PBMC) to the recombinant HCV proteins core, non-structural protein 3 (NS3), NS4, and NS5 in 14 patients with acute hepatitis C. All eight patients with self-limited disease compared with two of six with evolving chronic infection showed an NS3- specific PBMC response (p = 0.015). Of 65 patients with established chronic hepatitis C, five showed a PBMC response to NS3. NS3-specific CD4 T-cell clones from patients with self-limited infection predominantly produced interferon-gamma and may thus support cytotoxic effector mechanisms important for viral clearance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7475549     DOI: 10.1016/s0140-6736(95)91691-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  182 in total

Review 1.  Immunopathogenesis of viral hepatitis.

Authors:  M U Mondelli
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection.

Authors:  H M Diepolder; J T Gerlach; R Zachoval; R M Hoffmann; M C Jung; E A Wierenga; S Scholz; T Santantonio; M Houghton; S Southwood; A Sette; G R Pape
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus.

Authors:  N H Gruener; F Lechner; M C Jung; H Diepolder; T Gerlach; G Lauer; B Walker; J Sullivan; R Phillips; G R Pape; P Klenerman
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected].

Authors:  Krystle A Lang Kuhs; Arielle A Ginsberg; Jian Yan; Roger W Wiseman; Amir S Khan; Niranjan Y Sardesai; David H O'Connor; David B Weiner
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

5.  The clinical relevance of persistent recombinant immunoblot assay-indeterminate reactions: insights into the natural history of hepatitis C virus infection and implications for donor counseling.

Authors:  Addisalem T Makuria; Sukanya Raghuraman; Peter D Burbelo; Cathy C Cantilena; Robert D Allison; Joan Gibble; Barbara Rehermann; Harvey J Alter
Journal:  Transfusion       Date:  2012-02-05       Impact factor: 3.157

6.  Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.

Authors:  G Missale; R Bertoni; V Lamonaca; A Valli; M Massari; C Mori; M G Rumi; M Houghton; F Fiaccadori; C Ferrari
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

7.  Hepatitis C and HIV-1 coinfection.

Authors:  A H Mohsen; P Easterbrook; C B Taylor; S Norris
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

8.  Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses.

Authors:  Pablo Sarobe; Juan José Lasarte; Aintzane Zabaleta; Laura Arribillaga; Ainhoa Arina; Ignacio Melero; Francisco Borrás-Cuesta; Jesús Prieto
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 9.  Innate and Adaptive Immune Regulation During Chronic Viral Infections.

Authors:  Elina I Zuniga; Monica Macal; Gavin M Lewis; James A Harker
Journal:  Annu Rev Virol       Date:  2015-09-02       Impact factor: 10.431

Review 10.  Immune responses to HCV and other hepatitis viruses.

Authors:  Su-Hyung Park; Barbara Rehermann
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.